首页> 外文期刊>Diabetes care >Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas
【24h】

Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas

机译:具有DEND相关突变的儿童在KCNJ11相关的新生儿糖尿病中的视运动功能受损,并且可以通过早期使用磺脲类药物治疗来改善

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE - To assess performance on an age-standardized neuromotor coordination task among sulfonylurea-treated KCNJ11-related neonatal diabetic patients. RESEARCH DESIGN AND METHODS - Nineteen children carrying KCNJ11 mutations associated with isolated diabetes (R201H; n = 8), diabetes with neurodevelopmental impairment (V59M or V59A [V59M/A]; n = 8), or diabetes not consistently associated with neurodevelopmental disability (Y330C, E322K, or R201C; n = 3) were studied using the age-standardized Beery-Buktenica Developmental Test of Visual-Motor Integration (VMI). RESULTS - Although R201H subjects tested in the normal range (median standard score = 107), children with V59M/A mutations had significantly lower than expected VMI standard scores (median = 49). The scores for all three groups were significantly different from each other (P = 0.0017). The age of sulfonylurea initiation was inversely correlated with VMI scores in the V59M/A group (P < 0.05). CONCLUSIONS - Neurodevelopmental disability in KCNJ11-related diabetes includes visuomotor problems that may be ameliorated by early sulfonylurea treatment. Comprehensive longitudinal assessment on larger samples will be imperative.
机译:目的-评估磺脲类药物治疗的KCNJ11相关的新生儿糖尿病患者在年龄标准化的神经运动协调任务中的表现。研究设计和方法-19名携带KCNJ11突变的儿童与孤立的糖尿病(R201H; n = 8),具有神经发育障碍的糖尿病(V59M或V59A [V59M / A]; n = 8)或与神经发育障碍不一致的糖尿病(( Y330C,E322K或R201C; n = 3)是使用年龄标准化的比利-布克滕尼卡视觉电机整合(VMI)开发测试进行研究的。结果-尽管R201H受试者的测试在正常范围内(中位标准得分= 107),但具有V59M / A突变的儿童的VMI标准得分明显低于预期(中位= 49)。所有三组的得分均显着不同(P = 0.0017)。在V59M / A组中,磺酰脲起始的年龄与VMI得分呈负相关(P <0.05)。结论-与KCNJ11相关的糖尿病患者的神经发育障碍包括早期运动性磺酰脲类药物可缓解的视觉运动问题。必须对较大的样本进行全面的纵向评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号